Recent Updates
Recently added Catalysts
CNSY Positive Sentiment

Plus Therapeutics Highlights NCCN CNS Cancers Guidelines Update and Reinforces Clinical Role of CNSide® in Leptomeningeal Metastases Monitoring

Tuesday, July 14, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Plus Therapeutics announced that the updated NCCN guidelines continue to endorse cerebrospinal fluid (CSF) analysis for diagnosing and managing leptomeningeal metastases. The guidelines recommend CSF cytology follow-ups every 4 to 8 weeks for patients undergoing intrathecal therapy, highlighting the importance of ongoing patient monitoring.

Market Sentiment Analysis

POSITIVE FACTORS

  • NCCN guidelines support CSF analysis for leptomeningeal metastases.
  • Reinforcement of CNSide®'s role in patient monitoring.
  • Encouraging updates for intrathecal therapy management.

Full Press Release Details

Updated NCCN language continues to support CSF analysis in the diagnosis and management of leptomeningeal metastases, including CSF cytology follow-up every 4 to 8 weeks for patients receiving intrathecal therapy, to enable longitudinal patient monitoring HOUSTON, July 14, 2026 (GLOBE NEWSWIRE) --

Frequently Asked Questions

What do the updated NCCN guidelines support?

The updated NCCN guidelines support CSF analysis in diagnosing and managing leptomeningeal metastases.

How often should CSF cytology follow-ups occur?

CSF cytology follow-ups should occur every 4 to 8 weeks for patients receiving intrathecal therapy.

What is the role of CNSide® in patient monitoring?

CNSide® plays a crucial role in the longitudinal monitoring of patients with leptomeningeal metastases.

ShareAdd on Google
Tags: CNSY Viatris Investor Conferences Healthcare CNSide NCCN guidelines leptomeningeal metastases CSF analysis intrathecal therapy
Last updated: Jul 14, 2026

Biotech snapshot

Cash runway
$9M liquidity · $3M/mo burn
~3 mo
High dilution risk